Cue Biopharma Restructures to Focus on Autoimmune Initiatives

Cue Biopharma, a clinical-stage biopharmaceutical firm, has announced organisational restructure and a strategy focus on autoimmune initiatives to improve operational efficiencies and allow its cancer survival data to mature. The company's autoimmune program, CUE-401, and its depleting autoreactive B cell program, CUE-501, have advanced significantly. The business intends to maintain the potential value of its clinical cancer studies while directing resources into these initiatives. Cue Biopharma is proactively seeking external assistance via joint ventures and cooperation to advance these initiatives.

Cue Biopharma anticipates cutting its operational expenditures by around 25% in fiscal year 2025 by strategically realigning and giving priority to autoimmune initiatives. This will translate into an annual cash burn of about $30 million. In an effort to reduce capital requirements and increase operational efficiencies, the firm is also seeking further partnership support. Cue Biopharma has adjusted its labour requirements, leading to a 25% reduction in personnel in general and administrative, as well as research and development. It is anticipated that by realigning the staff and implementing targeted operational improvements, the company's cash runway will be extended until the middle of 2025.